USPSTF Shifts to a Neutral Position on Prostate-Specific Antigen Screening

The U.S. Preventive Services Task Force advises discussions of potential benefits and harms with middle-aged men who are interested in screening.

Sponsoring Organization: U.S. Preventive Services Task Force (USPSTF)

Target Audience: Primary care clinicians

Background

The USPSTF has updated its 2012 Grade D recommendation against prostate-specific antigen (PSA) screening for prostate cancer (NEJM JW Gen Med Jul 1 2012 and Ann Intern Med 2012; 157:120). This publication is the final version of the draft statement, released in 2017, that received substantial publicity (NEJM JW Gen Med May 15 2017). Public comment and research that has been published since the draft release did not result in any changes.

Key Recommendations

For middle-aged men (age range, 55–69), the USPSTF now recommends that clinicians discuss the potential benefits and harms of screening; decisions to undergo PSA screening…

Reviewing Authors

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

USPSTF Shifts to a Neutral Position on Prostate-Specific Antigen Screening

Topics

Background

Key Recommendations

Reviewing Authors